When reversible ligands do not reverse, and other modelers' dilemmas.
Slifstein
Mark
M
Columbia University, New York, New York, USA.
D001552:Benzazepines / Q000737:chemistry; D008024:Ligands; D008961:Models, Structural; D009420:Nervous System / Q000000981:diagnostic imaging*; D009536:Niacinamide / Q000031:analogs & derivatives / Q000737:chemistry; D049268:Positron-Emission Tomography / Q000639:trends*; D019275:Radiopharmaceuticals / Q000737:chemistry / Q000494:pharmacology*; D011955:Receptors, Drug / Q000378:metabolism*; D018100:Receptors, Histamine H3; D012015:Reference Standards; D015899:Tomography, Emission-Computed, Single-Photon
D001552:Benzazepines; D008024:Ligands; D019275:Radiopharmaceuticals; D011955:Receptors, Drug; D018100:Receptors, Histamine H3; D009536:Niacinamide; C521312:6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide